U.S.-based private equity firm Clayton, Dubilier & Rice has agreed to buy British healthcare marketing and services company Huntsworth for about 400 million pounds ($511 million) in a bet on continued strong growth in global healthcare markets. Clayton, Dubilier & Rice (CD&R) said on Tuesday it would pay 108 pence a share in cash for Huntsworth (HNTS.L), which provides marketing and medical communications services to pharmaceutical companies. That’s a 50% premium to the stock’s closing price on Monday. However, Huntsworth shares surged beyond the bid price to as high as 110.7 pence, suggesting some investors think a counter-bid is possible for the fast-growing British firm.
Read the full article: U.S. Buyout Firm CD&R to Buy UK’s Huntsworth for $511M in Pharma Bet //